Ontology highlight
ABSTRACT:
SUBMITTER: Ridley K
PROVIDER: S-EPMC7134581 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Ridley Kaden K Condren Michelle M
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20200101 3
Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel. Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the <i>CFTR</i> gene. This drug combination provides potential therapy to many patients who had previously been excluded from CFTR modulation therapy due to the nature of thei ...[more]